Indian stocks: Visit www.stage2stocks.com →

Nuvectis Pharma, Inc.

Stage 2 · Advancing · week 24

As of Oct 22, 2026, Nuvectis Pharma is in Stage 2, the uptrend phase, now in week 24 (since May 6, 2026). It closed at $20.89, 26.8% below its 52-week high and above its 200-day average, which is rising.

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. More about the company

$20.89
+0.92% today
$682M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is NVCT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 20w
S4 17w
S2 14w
S4 16w
S2 24w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 9w → S4 20w → S1 6w → S4 17w → S1 6w → S4 3w → S1 6w → S4 11w → S1 3w → S2 14w → S3 9w → S4 16w → S1 7w → S2 10w → S3 4w → S2 24w current
Total tracked: 166 weeks across 16 stage runs.

NVCT among Biotechnology24th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…24NVCTStage 2 · wk 2498−0.9%
vs 52W High
-26.8%
$5.65 lo$28.53 hi
26.8% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 24
1w13w26w
Week 24, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
46.0%
200 DMA: $14.31 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.56x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-0.9%
3M
+8.2%
6M
+137.7%
YTD
+145.5%
1Y
+247.0%
Scan Membership
Breakout Watch
Latest: 2025-03-12
2 appearances in last 60 days. First seen: 2023-03-07.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 24 · Vol 0.56x
2026-10-21S2
Wk 24 · Vol 0.88x
2026-10-20S2
Wk 24 · Vol 0.75x
2026-10-19S2
Wk 23 · Vol 1.01x
2026-10-16S2
Wk 23 · Vol 0.80x
2026-10-15S2
Wk 23 · Vol 0.79x
2026-10-14S2
Wk 23 · Vol 0.89x
2026-10-13S2
Wk 23 · Vol 1.04x
2026-10-12S2
Wk 22 · Vol 0.70x
2026-10-09S2
Wk 22 · Vol 0.73x
2026-10-08S2
Wk 22 · Vol 0.85x
2026-10-07S2
Wk 22 · Vol 0.57x
Moving averages & range
50 DMA
$21.70
200 DMA
$14.31
52W High
$28.53
52W Low
$5.65
5D Low
$18.60
Resistance levels (recent highs)
20d High
$21.92
60d High
$25.89
120d High
$28.53
250d High
$28.53
Next resistance
+4.9%
to 20d High
ROE
-214.6%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 61.4

Nuvectis Pharma: quick answers

What stage is Nuvectis Pharma in?

As of Oct 22, 2026, Nuvectis Pharma (NVCT) is in Stage 2, the uptrend phase. It entered Stage 2 on May 6, 2026 and is in week 24. What the four stages mean

Is Nuvectis Pharma in an uptrend?

Yes. Nuvectis Pharma is in a Stage 2 uptrend. It trades 46.0% above its 200-day average, which is rising.

How far is Nuvectis Pharma from its 52-week high?

Nuvectis Pharma closed at $20.89 on Oct 22, 2026, 26.8% below its 52-week high of $28.53. Its 52-week low is $5.65.

How has Nuvectis Pharma performed over the past year?

As of Oct 22, 2026, Nuvectis Pharma is up 247.0% over the past year and up 145.5% so far in 2026.

Which sector and industry is Nuvectis Pharma in?

Nuvectis Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.